

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

Manuscript NO: 84609

Title: Deltonin enhances gastric carcinoma cell apoptosis and chemosensitivity to cisplatin via inhibiting PI3K/AKT/mTOR and MAPK signaling axis

Provenance and peer review: Unsolicited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06520369

Position: Peer Reviewer

Academic degree: MD, PhD

Professional title: Assistant Lecturer, Doctor, Research Fellow

Reviewer's Country/Territory: Switzerland

Author's Country/Territory: China

Manuscript submission date: 2023-04-06

Reviewer chosen by: AI Technique

Reviewer accepted review: 2023-04-11 01:14

Reviewer performed review: 2023-04-17 02:10

Review time: 6 Days

Scientific quality	[] Grade A: Excellent [Y] Grade B: Very good [] Grade C: Good
	[] Grade D: Fair [] Grade E: Do not publish
Novelty of this manuscript	 [] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair [] Grade D: No novelty
Creativity or innovation of this manuscript	[] Grade A: Excellent[Y] Grade B: Good[] Grade C: Fair[] Grade D: No creativity or innovation



Baishideng

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

Scientific significance of the conclusion in this manuscript	 [] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair [] Grade D: No scientific significance
Language quality	[Y] Grade A: Priority publishing [] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	 [] Accept (High priority) [] Accept (General priority) [Y] Minor revision [] Major revision [] Rejection
Re-review	[Y]Yes []No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [] Onymous Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

Gastric carcinoma (GC) is a prevailing digestive tract cancer worldwide, which lacks of effective treatment. Here, Guo's group investigated the efficacy of Deltonin, an active ingredient of traditional Chinese medicine, for the therapy of GC. Meanwhile, the authors discussed the underlying mechanism of Deltonin to boost GC cells' chemosensitivity to cisplatin via inactivating p38-MAPK and PI3K/AKT/mTOR signals. In a nutshell, this study is instructive, and the experimental methods and data can well support the conclusion of this paper. I have only two minor queries about this paper: 1) Compared with the existing chemoradiotherapy in clinical, what is the key advantage of Deltonin for treating GC? 2) As for the in-vivo experiments, why just using female nude mice?



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

Manuscript NO: 84609

Title: Deltonin enhances gastric carcinoma cell apoptosis and chemosensitivity to cisplatin via inhibiting PI3K/AKT/mTOR and MAPK signaling axis

Provenance and peer review: Unsolicited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06519760

Position: Peer Reviewer

Academic degree: MD

Professional title: Assistant Lecturer, Research Assistant

Reviewer's Country/Territory: India

Author's Country/Territory: China

Manuscript submission date: 2023-04-06

Reviewer chosen by: AI Technique

Reviewer accepted review: 2023-04-10 02:42

Reviewer performed review: 2023-04-18 02:13

Review time: 7 Days and 23 Hours

	[] Grade A: Excellent [] Grade B: Very good [Y] Grade C:
Scientific quality	Good
	[] Grade D: Fair [] Grade E: Do not publish
Novelty of this manuscript	[] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair [] Grade D: No novelty
Creativity or innovation of	[] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair
this manuscript	[] Grade D: No creativity or innovation



Baishideng

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA Telephone: +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

Scientific significance of the conclusion in this manuscript	 [] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair [] Grade D: No scientific significance
Language quality	[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	 [] Accept (High priority) [] Accept (General priority) [Y] Minor revision [] Major revision [] Rejection
Re-review	[Y]Yes []No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [] Onymous Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

In this manuscript, the authors aimed at exploring the role of Deltonin in enhancing gastric carcinoma cell apoptosis and chemosensitivity to cisplatin. In vitro and in vivo experiments have been used to verify the therapeutical effect of Deltonin. The results showed that Deltonin directly induced the apoptosis of GC AGS, HGC-27, and stepped up GC cells' chemosensitivity to cisplatin via repressing GC cell proliferation and growth and accelerating apoptosis. So, in my opinion, this manuscript is well-written. The experimental design is reasonable, and the results reflects the conclusion as well. I recommend its acceptance after minor revision. The detailed comments are as follows: 1. In this article, the authors have demonstrated that Deltonin boosted GC cells' chemosensitivity to cisplatin via inactivating p38-MAPK and PI3K/AKT/mTOR signals. So, what is the motivation of the author to investigate the combined treatment of Deltonin and cisplatin for GC? 2. In addition to cisplatin, did the authors tested other anti-cancer drugs combined with Deltonin?